新股消息 | 天辰生物医药递表港交所 自主研发针对过敏性疾病及自身免疫性疾病创新药

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1][3]. Company Overview - Tianchen Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative drugs targeting allergic and autoimmune diseases, with a comprehensive pipeline of biological products across various medical fields [3][4]. Market Potential - The global autoimmune disease drug market is projected to grow from $138.9 billion in 2024 to $176.7 billion by 2030, with a compound annual growth rate (CAGR) of 4.1%. In China, the market is expected to increase from $5.1 billion in 2024 to $19 billion by 2030, with a CAGR of 24.5% [3]. - The global allergy disease drug market is anticipated to rise from $42.8 billion in 2018 to $68.8 billion by 2024, with a CAGR of 8.2%, and is expected to reach $111.4 billion by 2030, reflecting a CAGR of 8.4% during this period [3]. Product Pipeline - The core product, LP-003, is a next-generation anti-IgE antibody designed to treat allergic diseases, including allergic rhinitis (AR) and chronic spontaneous urticaria (CSU). It is noted for being the fastest in clinical development among next-generation anti-IgE biological candidates globally [4][5]. - The key product, LP-005, is a dual-function antibody fusion protein targeting C5 and C3b complement, aimed at treating paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated kidney diseases [4][6]. Clinical Development - LP-003 has received IND approval for multiple indications in China and is currently undergoing a Phase III clinical trial for seasonal AR, with plans to submit a BLA to the National Medical Products Administration by Q3 2026. A head-to-head Phase II trial against omalizumab for CSU is also in progress [5]. - For LP-005, IND approvals have been obtained for various indications, and a Phase II clinical trial is currently evaluating its efficacy in treating PNH [6]. Financial Overview - For the fiscal years ending December 31 and the six months ending June 30, Tianchen Biopharmaceuticals reported other income and revenue of approximately RMB 2.23 million, RMB 3.07 million, RMB 1.38 million, and RMB 0.879 million, respectively. The total loss for the same periods was approximately RMB 95.78 million, RMB 137.32 million, RMB 58.93 million, and RMB 94.21 million [6][7].